PRNewsWire
03 Aug 2026, 05:00 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Capricor Therapeutics allegedly changed the statistical analysis plan for its Deramiocel clinical data without prior FDA agreement before resubmitting its Biologics License Application (BLA). — Unauthorized changes to clinical analysis plans significantly increase the risk of FDA rejection, threatening the company's primary product pipeline.
-0.80A securities fraud class action lawsuit has been filed against Capricor Therapeutics (NASDAQ: CAPR) alleging false and misleading statements regarding its BLA effectiveness. — Class action lawsuits create legal liabilities and signal institutional distrust in management's transparency.
-0.50Which stocks this story touches
The company is mentioned as the subject of a securities fraud class action lawsuit.
Continue reading
6 related stories
Search tags
The company is facing a class action securities fraud lawsuit alleging false and misleading statements regarding clinical data and FDA approval.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
